Admedus announced on 25 August 2016 that the manufacturing team have met the internal timeline of being prepared for the manufacture of VascuCel for the November launch date.
“We are very excited to be able to add products to the portfolio which provide much needed alternatives to surgeons and patients in the vascular repair space” stated Wayne Paterson, chair and interim CEO.
After months of intense review and implementation of manufacturing systems, the Malaga factory will be ready to supply VascuCel alongside its current output of CardioCel by 1 November 2016.
VascuCel is an exciting new product for use in repair of vascular surgical procedures such as carotid endarterectomy (CEA), coronary revascularisation, vascular aneurysm repairs and other vascular repairs, addressing a market worth in excess of USD$500 million per annum. In the US market there are over 170,000 CEA procedures performed each year and many more globally.
The VascuCel product will have the characteristics and patient benefits of the ADAPT tissue as experienced with CardioCel, such as the lack of calcification recently reported for CardioCel after over eight years post implantation. Data also show ADAPT tissue has unique remodelling properties giving patients and surgeons both short and longer-term benefits in repairing vascular defects.
